TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections
Amicus Therapeutics Inc. (NASDAQ:FOLD) is one of the 13 hot stocks to buy with the highest upside potential.
Amicus Therapeutics Inc. (FOLD)
This company is not actively trading or the ticker does belong to another company in our database now.
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Syquant Capital Olivier Leymarie And Henri Jeantet | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.49 | 1,500 | $15,735.00 | 65,082 | 2021-11-01 | Filing | |
| $9.56 | 1,500 | $14,346.00 | 63,582 | 2021-10-01 | Filing | |
| $11.41 | 1,500 | $17,115.00 | 62,082 | 2021-09-01 | Filing | |
| $9.28 | 1,500 | $13,920.00 | 60,582 | 2021-08-02 | Filing | |
| $9.24 | 1,500 | $13,861.20 | 47,467 | 2021-06-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.35 | 22,500 | $322,839.00 | 998,680 | 2026-03-02 | Filing | |
| $14.31 | 75,000 | $1,073,182.50 | 1,021,180 | 2026-01-20 | Filing | |
| $14.17 | 25,642 | $363,380.47 | 245,690 | 2025-12-19 | Filing | |
| $10.86 | 77,926 | $846,011.41 | 1,129,782 | 2025-12-15 | Filing | |
| $11.00 | 25,643 | $282,073.00 | 271,332 | 2025-12-15 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
13 Hot Stocks to Buy with the Highest Upside Potential
On average, equities are expected continue to deliver positive results in 2026, this time with greater breadth across sectors, styles, and regions, compared to the other periods of the recent bull market...
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments
TheFly reported on January 22 that Jefferies downgraded FOLD to Buy from Hold and lowered the price target to $14.50 from $16. The company got substantial pharmaceutical takeover interest outside of...
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger
Amicus Therapeutics soared to a new 52-week high on Friday, jumping 30.21 percent to close at $14.18 apiece as investors gobbled up shares following announcements that it would merge with Biomarin Pharmaceutical...
Amicus Therapeutics (FOLD) Soars to 52-Week High on 'Strong Buy' Reco
In a market report, Zacks Research issued a “strong buy” recommendation for Amicus Therapeutics, Inc.
Goldman Sachs Bullish on Amicus Therapeutics (FOLD) Following Q3 2025 Results
The revision follows the company’s performance in the third quarter, marked by the first positive GAAP net income and solid revenue execution.
15 Stocks Set to Explode in 2026
While the market figures out whether artificial intelligence is driving the next bubble or the next industrial revolution, a quiet rotation of capital into the next wave of growth leaders outside Big ...
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Amicus Therapeutics Third Quarter 2025 Financial Results Conference Call and webcast.
What Does Wall Street Think About Amicus Therapeutics (FOLD)?
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best biotech stocks with high potential. On September 18, Needham analyst Gil Blum upgraded the rating on Amicus Therapeutics, Inc.
Hedge Fund Resource Center